Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivBayer files lawsuit against Johnson & Johnson, Janssen BiotechFebruary 23, 20263:43 PM UTCUpdated agoBy ReutersThe 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical... Purchase Licensing Rights, opens new tab Read moreCompaniesBayer AGJanssen Biotech IncJohnson ...

Core Insights - Johnson & Johnson (JNJ) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in immunology, oncology, and neuroscience, alongside J&J's extensive medical devices business [1] - Both companies are facing patent challenges, necessitating effective pipeline execution and business development for sustained growth [2] Company Overview Johnson & Johnson (JNJ) - JNJ's diversified business model includes pharmaceuticals and medical devices, with over 275 subsidiaries and 28 products generating over $1 billion in annual sales [4] - The Innovative Medicine unit showed a 4.1% organic sales growth in 2025, driven by key drugs like Darzalex and new products [5] - JNJ's MedTech business saw a 4.3% organic sales increase in 2025, supported by acquisitions and improvements in various segments [6] - Significant R&D investments exceeding $32 billion in 2025, with new product approvals expected to drive future growth [7] - JNJ anticipates that 10 new products could achieve peak sales of $5 billion each [8] AbbVie (ABBV) - AbbVie successfully transitioned from the loss of exclusivity (LOE) of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which contributed to a combined sales growth of over 40% in 2025 [9][10] - The neuroscience portfolio also saw a nearly 20% sales increase, driven by products like Botox and Vraylar [12] - AbbVie has invested over $5 billion in acquisitions to enhance its early-stage pipeline, particularly in immunology [13] - The aesthetics segment faced challenges, with global sales declining by 5.9% in 2025 [14] Financial Performance - JNJ's stock rose 48% in the past year, while AbbVie's stock increased by 10.2%, both outperforming the industry average of 12.1% [20] - The Zacks Consensus Estimate for JNJ's 2026 sales and EPS indicates a year-over-year increase of 6.5% and 7.0%, respectively [15] - AbbVie's 2026 sales and EPS estimates imply a year-over-year increase of 9.4% and 8.74%, respectively [17] Valuation and Yield - AbbVie appears more attractive from a valuation perspective, trading at a forward P/E ratio of 15.25 compared to JNJ's 20.79 [20] - AbbVie offers a higher dividend yield of approximately 3.1%, compared to JNJ's 2.1% [23] Future Outlook - AbbVie expects high single-digit revenue growth through 2029, driven by Skyrizi and Rinvoq, with no significant LOE events anticipated [27] - JNJ aims for approximately $100 billion in revenues in 2026, with expectations of sales growth across both segments [28] - Both companies are positioned for continued growth, with JNJ showing a slight edge in stock performance and analyst estimates [29]

Core Insights - The European Commission has approved subcutaneous (SC) amivantamab, allowing for administration in minutes rather than hours, with efficacy and safety consistent with intravenous (IV) amivantamab [1][2][3] - SC amivantamab is now authorized for all previously approved IV indications, including every-four-week (Q4W) and every-three-week (Q3W) dosing regimens for advanced non-small cell lung cancer (NSCLC) [1][2][3][4] - The new dosing options aim to reduce administration-related reactions and improve patient convenience [1][2][3][4] Company Developments - Johnson & Johnson announced the approval of SC amivantamab, which is expected to enhance the treatment experience for patients with EGFR-mutated NSCLC [1][2][3] - The approval is part of Johnson & Johnson's commitment to improving patient care and treatment flexibility [1][2][3] Clinical Study Results - The approval is supported by Phase 2 PALOMA-2 and Phase 1 PALOMA studies, which demonstrated that SC amivantamab has a response rate and safety profile similar to IV amivantamab, but with significantly fewer administration-related reactions [1][2][3][4] - Administration time for SC amivantamab is approximately five minutes, compared to five hours for the first IV infusion [1][2][3][4] Treatment Context - Amivantamab is a bispecific antibody targeting EGFR and MET mutations, which are prevalent in NSCLC [3][4] - The approval of SC amivantamab aligns with the growing need for more efficient treatment options in the context of lung cancer, which is the leading cause of cancer-related deaths in Europe [6][7]

Company Overview - Johnson & Johnson (J&J) is a leading company in the multitrillion-dollar global healthcare industry, with total healthcare spending in the U.S. surpassing $5.3 trillion in 2024 and growing at mid- to high single-digit rates [3] - The company develops and sells a wide range of pharmaceutical drugs and medical devices, with over 75% of its sales coming from products that hold top-two market share positions in their respective applications [4] Financial Strength - J&J has a strong financial position, allowing it to invest in new product development, acquire emerging competitors, and consistently raise its dividend [5] - The stock currently yields 2.1%, with management having raised the dividend for 63 consecutive years, making it a reliable income source for investors [6] - J&J is one of only two companies with the highest available credit rating (AAA), ensuring access to debt when needed [6] Market Position and Growth Potential - With a market capitalization approaching $590 billion, J&J is one of the world's largest companies, indicating stability rather than rapid wealth generation [7] - Management believes that the business could accelerate to double-digit growth by the end of this decade, suggesting potential upside for investors [7]

Core Viewpoint - Johnson & Johnson is considered a stable investment option, providing steady income and strong total returns, making it a reliable choice for investors seeking long-term growth [1]. Group 1: Dividend Performance - Johnson & Johnson has raised its dividend for 63 consecutive years, qualifying it as a "Dividend King" [3]. - The company has achieved a total dividend increase of 73% over the past decade, with a recent quarterly payout increase of 4.8% to $1.30 per share, resulting in a yield of 2.1% [4]. - The payout ratio stands at 46.3%, indicating sufficient capacity for continued dividend increases, with $12.4 billion paid in dividends against $20 billion in free cash flow in 2025 [5]. Group 2: Financial Performance - Over the past year, Johnson & Johnson's total return exceeded 60%, significantly outpacing the S&P 500's return [7]. - The company reported a revenue increase of 6% to $94.2 billion and a remarkable 90.5% growth in earnings per share (EPS) to $11.03, with adjusted EPS rising by 8.1% to $10.79 [8]. Group 3: Future Growth and Innovation - Johnson & Johnson is investing $1 billion in a new cell manufacturing facility in Pennsylvania, aiming to enhance domestic production of advanced medicines [9]. - The company plans to allocate $55 billion towards U.S. manufacturing, research and development, and technology through early 2029 [10]. - In 2025, Johnson & Johnson invested $14.6 billion in R&D, leading to 28 programs generating over $1 billion in sales and 51 approved therapies in its innovative medicine division [11].

FDA Designation - The FDA granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as a monotherapy for adults with advanced head and neck squamous cell carcinoma [1] - The designation is for patients with recurrent or metastatic cancer that is HPV-unrelated after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [2] - Rybrevant Faspro is also approved for multiple settings in locally advanced or metastatic non-small cell lung cancer and is being evaluated in additional solid tumors, including colorectal cancer [2] Clinical Studies - The Breakthrough Therapy Designation is supported by data from the open-label Phase 1b/2 OrigAMI-4 study, which showed promising clinical activity with rapid and durable responses in a heavily pretreated patient population [3] - Subcutaneous amivantamab is being further evaluated in the ongoing Phase 3 OrigAMI-5 study, assessing its combination with Merck's Keytruda and carboplatin versus 5-fluorouracil plus pembrolizumab and platinum-based chemotherapy for HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma [4] New Dosing Schedule - The FDA approved a new, simplified monthly dosing schedule for Rybrevant Faspro in combination with oral Lazcluze for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer [5] Contract Extension - Trellus Health plc extended its contract with Johnson & Johnson's Health Care Systems unit for six months to continue providing Trellus Elevate for patients with moderate to severely active inflammatory bowel disease [6] - The extension was influenced by the achievement of engagement and satisfaction metrics during the initial pilot phase [6]

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios designed for income investors, including retirees, featuring three buy-and-hold portfolios, three rotational portfolios, and a conservative NPP strategy portfolio [1] - The portfolios include two high-income portfolios, two dividend growth investing (DGI) portfolios, and a conservative NPP strategy portfolio aimed at low drawdowns and high growth [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for 30% lower drawdowns and 6% current income [2] - The service is managed by a financial writer with 25 years of investment experience, emphasizing strategies for stable, long-term passive income [2]

Core Insights - Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical and endoscopic remission in ulcerative colitis patients over three years, with over 80% of patients in clinical remission and more than 50% in endoscopic remission at Week 140 [1][2]. Group 1: Clinical Efficacy - At Week 140, 80.8% of patients treated with TREMFYA® were in clinical remission, while 53.6% achieved endoscopic remission [1]. - 78.6% of patients experienced histo-endoscopic mucosal improvement (HEMI), indicating significant intestinal healing [1]. - Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, demonstrating sustained efficacy [1]. Group 2: Study Retention and Safety - Approximately 89% of eligible study participants completed treatment through Week 140, indicating high retention rates [1]. - No new safety concerns were reported during the study, reinforcing the long-term safety profile of TREMFYA® [1][2]. Group 3: Mechanism and Approval - TREMFYA® is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting immune-mediated diseases [1][2]. - The drug has received FDA and European Commission approval for treating both moderately to severely active Crohn's disease and ulcerative colitis [1][2]. Group 4: Additional Research and Commitment - Johnson & Johnson presented 30 abstracts at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, highlighting ongoing research and commitment to inflammatory bowel disease treatments [1]. - Two other abstracts from Johnson & Johnson were recognized as Top 10 oral abstracts, showcasing the company's dedication to advancing treatment options [1].

The Dow Jones Industrial Average (^DJI) was up 230.81 (+0.47%) points today, Friday, February 20th, 2026, closing at a record 49,625.97. Similarly, Dow Futures (YM=F) climbed 221.00 (+0.45%) to 49,679.00. The primary narrative driving the market was a favorable economic data release regarding cooling inflation, which bolstered investor confidence in a potential Federal Reserve pivot. This shift in sentiment favored high-growth technology and e-commerce stocks, which led the broader index higher despite loca ...

A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 13% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Johnson & Johnson before we dive into how investors and analysts ...